Indeed, in the Golestan cohort followed for up to 14 years, Hosen et al. identified the presence of TERT promoter mutations in urine samples of 47% asymptomatic individuals, who subsequently developed primary bladder cancer, and in none of matched controls who did not develop bladder cancer (Hosen et al., 2020). This evidence concerns the gene TERT and urinary bladder carcinoma.